Thalia Therapeutics Plc (FRA:0GO)

Market Cap	5.52M +136.7%
Revenue (ttm)	8.24K +20.6%
Net Income	-1.29M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0005
Previous Close	0.0005
Day's Range	0.0005 - 0.0005
52-Week Range	0.0005 - 0.0260
Beta	n/a
RSI	47.12
Earnings Date	Jun 25, 2026

About Thalia Therapeutics

Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1979
• Employees: 4
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0GO

Financial Performance

In 2024, Thalia Therapeutics's revenue was 7,282, an increase of 272.86% compared to the previous year's 1,953. Losses were -1.06 million, -16.60% less than in 2023.

Financial numbers in GBP